Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [5]. Core Insights - The company is expected to continue its growth momentum in Q2 2025, driven by the launch of 9 new products in May, including popular IPs like Conan and Transformers [1]. - The introduction of the Minions product line enhances user engagement and brand image through interactive features and a 5-month exhibition tour across 6 cities [2]. - The company's global strategy is advancing, with participation in the CCXP Mexico event, showcasing various well-known IPs and aiming to penetrate the Latin American market [3]. - The BFC creation competition has gained significant traction, with nearly 8,000 events held across 120 cities, indicating increased community engagement and brand loyalty [4]. - Profit forecasts for 2025-2027 are projected at 960 million, 1.48 billion, and 2.08 billion yuan, with corresponding PE ratios of 50, 32, and 23 [5]. Summary by Sections New Product Launches - In May, the company launched 9 new products, indicating a strong pipeline and potential for continued growth in Q2 [1]. User Engagement and Brand Image - The Minions product line features 6 popular characters with enhanced interactive designs and a nationwide exhibition to boost user engagement [2]. Global Expansion - The company showcased its products at a major Latin American cultural event, reinforcing its commitment to global market penetration [3]. Community Engagement - The BFC creation competition has seen a significant increase in participation, enhancing community vitality and brand stickiness [4]. Financial Projections - The company maintains its profit forecasts for the next three years, indicating confidence in its growth trajectory [5].

研究报告 Research Report 9 Jun 2025 信达生物 Innovent Biologics (1801 HK) 2025 ASCO 数据超预期，创新潜力不断兑现 2025 ASCO Data Beats Expectations, Validating Sustained Innovation Execution [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$73.15 目标价 HK$90.10 HTI ESG 3.6-1.4-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$120.81bn / US$15.40bn 日交易额 (3 个月均值) US$146.21mn 发行股票数目 1,652mn 自由流通股 (%) 93% 1 年股价最高最低值 HK$74.25-HK$30.00 注：现价 HK$73.15 为 2025 年 06 月 06 ...

Investment Rating - The report assigns an "Overweight" rating to Pop Mart International Group with a price target of HK$302.00, indicating a 17% upside from the current price of HK$258.80 [7]. Core Insights - Pop Mart's IP versatility and operational skills are expected to drive enduring growth, with sales projected to increase from US$3.6 billion in 2025 to US$6 billion in 2027, making it one of the fastest-growing global consumer brands [2][37]. - The market has likely priced in Pop Mart's growth for 2025, but there is potential for long-term scale that remains unaccounted for [3][42]. - The company's earnings estimates have been upgraded, with EPS projections increasing by 6% for 2025, 15% for 2026, and 21% for 2027, reflecting a clearer growth path in North America and Europe [4]. Summary by Sections Market Position and Growth Potential - Pop Mart's exponential growth in North America and Europe has exceeded expectations, driven by strong social media engagement and consumer enthusiasm [2][9]. - The total market for IP products is estimated to be significantly larger than the current figures, with Pop Mart expected to capture a 6-7% share among its peers by 2027 [44][45]. Financial Performance and Projections - The report projects Pop Mart's revenue to rise from US$0.9 billion in 2023 to US$6.0 billion in 2027, indicating a rapid growth trajectory [37]. - The company's net income is expected to reach Rmb7.3 billion, Rmb10.4 billion, and Rmb13.2 billion for 2025, 2026, and 2027, respectively, which is significantly higher than consensus estimates [58]. Competitive Landscape - Pop Mart is more vertically integrated than its peers, owning its IPs and operating a direct-to-consumer model, which enhances its profitability [48]. - The report highlights that Pop Mart's operational model allows for a higher operating profit margin compared to traditional licensing models used by competitors like Disney and Sanrio [48][84]. New Initiatives and Diversification - Pop Mart is expanding into new business areas such as theme parks (Pop Land) and fashion jewelry (POPOP), which are expected to contribute significantly to revenue in the long term [64][70]. - The company plans to leverage its IPs in these new ventures, aiming to create a comprehensive ecosystem that enhances brand visibility and consumer engagement [69][75].

[Table_Industry] 运输设备业 净利率同比提升，关注纯电新车周期 理想汽车-W(2015) ——理想汽车 2025 年一季度业绩点评 股票研究 /[Table_Date] 2025.06.09 2025-06-09 [Table_Invest] 评级： 增持 [Table_CurPrice] 当前价格(港元)： 110.00 本报告导读： 理想汽车 25Q1 营收 259 亿元，同比+1%；归母净利润 6.5 亿元，同比+9%。我们看 好公司 AI 能力+纯电新车周期，维持"优于大市"评级。 投资要点： | [Table_Finance] 财务摘要（百万人民币） | 2022A | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | --- | | 营业收入 | 45287 | 123851 | 144460 | 168455 | 223371 | 267144 | | (+/-)% | 68% | 173% | 17% | 17% | 33% | 20% | | 毛利润 | 8790 | 2 ...

Investment Rating - The report maintains an "OUTPERFORM" rating for Innovent Biologics with a target price of HK$90.10, up from a previous target of HK$62.50 [2][10]. Core Insights - Innovent Biologics showcased its strong oncology R&D capabilities at the 2025 ASCO Annual Meeting, with eight studies selected for oral presentation, highlighting the efficacy and safety of IBI363 and IBI343 in various cancer types [3][15][16]. - The data presented for IBI363 in advanced non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) indicates its potential as a backbone therapy for next-generation immuno-oncology treatments, demonstrating robust tumor responses and long-term survival benefits [4][16]. Financial Summary - Revenue projections for Innovent Biologics are set at RMB 11.86 billion for 2025, with a growth rate of 26% compared to the previous year, and expected to reach RMB 18.17 billion by 2027 [10][13]. - The company is projected to turn profitable in 2025, with a net profit of RMB 384 million, and further growth to RMB 1.77 billion by 2027 [10][13]. Clinical Data Highlights - IBI363 monotherapy showed a median progression-free survival (mPFS) of 9.3 months in advanced NSCLC, outperforming standard therapies [5][19]. - In MSS-type colorectal cancer patients, IBI363 demonstrated a median overall survival (mOS) of 16.1 months, significantly longer than the typical 9-10 months seen with current therapies [8][20]. - The efficacy of IBI363 in treating acral and mucosal melanoma was also notable, achieving a confirmed objective response rate (ORR) of 23.3% in a historically difficult-to-treat population [22].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][7]. Core Insights - The company is a leader in waste incineration, with a significant cash flow turning point expected, leading to potential increases in dividends [6][7]. - The company has a total waste-to-energy capacity of 150,400 tons/day, ranking first in the industry, and is supported by its major shareholder, China Everbright Group, which holds 43.07% of the company [6][21]. - The report anticipates a recovery in profitability due to improved operational income, reduced impairment, and lower financial costs [6][54]. Summary by Sections Company Overview - The company has been focused on environmental protection for over 20 years, with a waste incineration capacity of 150,400 tons/day as of the end of 2024, leading the industry [17][28]. - The company operates in three main segments: Environmental Energy, Green Environmental Protection, and Water Services, with the Environmental Energy segment contributing 87% to the net profit in 2024 [6][24]. Financial Summary and Profit Forecast - The company’s revenue for 2024 is projected at HKD 30,258 million, with a year-on-year decline of 7%, and a net profit of HKD 3,377 million, down 24% year-on-year [5][54]. - The report forecasts net profits for 2025-2027 to be HKD 3,589 million, HKD 3,810 million, and HKD 4,055 million respectively, with a price-to-earnings ratio of 8x leading to a target market value of HKD 28,710 million, indicating a 23% upside potential [5][7]. Operational Improvements - The company has seen a significant reduction in capital expenditures (Capex), from HKD 22.8 billion in 2021 to HKD 5.1 billion in 2024, contributing to a positive free cash flow of HKD 4.416 billion for the first time [6][7]. - The operating cash flow is expected to improve due to accelerated national subsidies, with an adjusted operating cash flow of HKD 9.52 billion anticipated for 2024 [6][7]. Dividend Potential - The company has a current dividend yield of 6.04%, with a historical dividend payout ratio of approximately 31%, expected to increase to 42% in 2024 [6][7]. - The report suggests that with improving profits and cash flow, there is significant potential for future dividend increases [6][7]. Market Perception - The market has not fully recognized the company's potential for profit recovery and dividend increases, primarily due to the complexity of its financial statements [9][10].

传媒 2025 年 06 月 09 日 快手-W (01024) ——可灵商业化超预期，看好 AI 带来业绩和估值弹性 上 市 公 司 报告原因：有新的信息需要补充 买入（维持） | 市场数据： | 2025 年 06 月 06 日 | | --- | --- | | 收盘价（港币） | 59.10 | | 恒生中国企业指数 | 8629.75 | | 52 周最高/最低（港币） | 68.90/37.55 | | H 股市值（亿港币） | 2,536.29 | | 流通 H 股（百万股） | 3,560.90 | | 汇率（人民币/港币） | 1.0920 | 一年内股价与基准指数对比走势： -29% 21% 71% HSCEI 快手-W 资料来源：Bloomberg 证券分析师 林起贤 A0230519060002 linqx@swsresearch.com 任梦妮 A0230521100005 renmn@swsresearch.com 联系人 林起贤 (8621)23297818× linqx@swsresearch.com 投资要点： 财务数据及盈利预测 | | 2023 | 2024 | 2025 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 74.58 HKD per share, based on a 15x PE valuation for 2025 [4][5]. Core Insights - The company has shown significant progress in its commercial operations, particularly with its Kuaishou Keling product, which achieved monthly revenues exceeding 1 billion CNY in April and May [3][8]. - The Keling 2.1 version was launched at the end of May, offering a higher cost-performance ratio, which is expected to drive user growth and increase paid subscriptions [8]. - The company is experiencing a positive cycle of technology iteration, product refinement, user payment, and revenue growth, similar to the trajectory of overseas competitors [8]. Financial Forecasts - The adjusted net profit for the company is projected to be 195 billion CNY in 2025, with expected growth to 246 billion CNY by 2027 [4][9]. - Revenue is forecasted to grow from 113.47 billion CNY in 2023 to 164.14 billion CNY in 2027, reflecting a compound annual growth rate [9][10]. - The gross margin is expected to improve from 50.6% in 2023 to 56.7% in 2027, indicating enhanced operational efficiency [9][11]. Performance Metrics - The company's stock price performance has shown a 20% increase over the past month and an 18.97% increase over the past week [6]. - The company has repurchased shares worth 19 billion HKD since the beginning of 2025, providing a safety net for shareholder returns [8].

买入 全面升级为全栈 AI 产品和服务商，探索数字货币和 RWA 中国软件国际（354.HK） 2025-6-9 星期一 【投资要点】 ➢ 2024 年收入和利润相对稳定，AIGC 新业务成增长亮点 2024 全年公司实现收入 169.5 亿元人民币（-1.0%），归母净利润 5.1 亿元 人民币（-28.1%）。H2 财务环比回升，显示新业务拉动初现。全年经营活 动现金流净额 6.03 亿元，同比下降 16.3%。 ➢ 全栈 AIGC 能力体系加速成型，战略转型进入规模化落地阶段 公司加快 AIGC 战略落地，构建以"模型工场 2.0"和"Agent 工厂"为核 心的一体化能力体系，推动 AI 产品在多个行业场景中规模化复制，标志公 司由技术投入迈向商业化阶段。2024 年"全栈 AI 产品及服务"收入达人民 币 9.57 亿元，占集团总收入的 5.6%。其中，下半年该板块收入环比大幅上 升 135.44%，成为推动集团业绩触底反弹的关键动力之一。 ➢ 持续深化与华为生态合作，推动信创产品化落地 公司深化与华为合作，拓展 KaihongOS 在智能终端与开发工具链应用，并 完成超 200 个华为云 CTSP ...

$${\mathfrak{H}}\lambda$$ 信义能源（3868.HK） 2025-06-09 星期一 | 目标价： | | 1.30 | 港元 | | --- | --- | --- | --- | | 现 | 价： | 1.06 | 港元 | | 预计升幅： | | 23% | | 重要数据 | 日期 | 2025-6-6 | | --- | --- | | 收盘价（港元） | 1.06 | | 总股本（亿股） | 83.77 | | 总市值（亿港元） | 89 | | 净资产（亿元） | 125 | | 总资产（亿元） | 217 | | 52 周高低（港元） | 1.14/0.64 | | 每股净资产（元） | 1.49 | 数据来源: Wind 、国元证券经纪(香港)整理 主要股东 信义光能 (51.62%) 上海宁泉资产 (8.01%) 李贤义 (6.97%) 信义玻璃 (5.54%) 相关报告 首次报告-20201209 更新报告-20210310 更新报告-20210818 更新报告-20220309/0808 更新报告-20230609/20240313/0809 研究部 | 姓名：杨 ...